Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 studyQing Zhou, Yi‐Long Wu, Cheng Huang et al.|Cancer Cell|2021Cited by 232
Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor CellsBen‐Yuan Jiang, Yi‐Long Wu, Yang-Si Li et al.|Clinical Cancer Research|2017Cited by 136
Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trialSi‐Yang Maggie Liu, Yi‐Long Wu, Xiaorong Dong et al.|EClinicalMedicine|2023Cited by 11
Genomic and immune characteristics of <i>HER2</i>‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapyHai‐Yan Tu, Yi‐Long Wu, Bing‐Chao Wang et al.|Molecular Oncology|2023Cited by 9
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)Huajun Chen, Yi‐Long Wu, Hai‐Yan Tu et al.|Journal of Hematology & Oncology|2025Cited by 9